[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-asthma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-asthma":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100644848",false,"NCT07675044","Quantifying the Burden of Type 2 (T2) Inflammation in Asthma","QUANTAS-PC: Quantifying the Burden of Type 2 (T2) Inflammation in Asthma in Primary Care and Community Specialty Practices","QUANTAS","Participant Inclusion Criteria\n\n* Age 18 years and older\n* Ability to consent and comply with protocol assessments\n* Pre-existing diagnosis of asthma and has started treatment\n\nParticipant Exclusion Criteria\n\n* Participant deemed medically ineligible per the opinion of the investigator\n* History of respiratory\u002Flung disease other than asthma (e.g., COPD, emphysema, chronic bronchitis, tuberculosis, cystic fibrosis, lung cancer, recurrent pneumonia or other chronic lung disease)\n* Participants who meet criteria for GINA 5, severe asthma (ICS + additional controllers)\n* Current Enrollment in an asthma intervention trial that could affect asthma outcomes clinically and T2 biomarkers\n* Visit with a specialist (i.e. Pulmonologist or Allergist) in the past year who is measuring FeNO levels","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.",[24,25],"Asthma","Type 2 Asthma",[24,27,28],"Eosinophils","Exhaled Nitric Oxide","NOT_YET_RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":20},"2026-07",{"date":37,"type":20},"2027-05",{"name":39,"class":40},"Icahn School of Medicine at Mount Sinai","OTHER",""]